Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer

Fasching P.A.Delea T.E.YEN-SHEN LUDe Boer R.Hurvitz S.A.Moynahan A.Chandiwana D.Lanoue B.Hu H.Thuerigen A.O��shaughnessy J.2022-03-102022-03-1020211179-1322https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121039413&doi=10.2147%2fCMAR.S325043&partnerID=40&md5=9c5ed97c0a25948ee637509170f20240https://scholars.lib.ntu.edu.tw/handle/123456789/597070[SDGs]SDG3Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancerjournal article10.2147/CMAR.S3250432-s2.0-85121039413